Albireo Pharma's late-stage candidate A4250 was given rare pediatric disease status by the FDA. The drug is being developed as a treatment of progressive familial intrahepatic cholestasis.
FDA grants rare pediatric disease status to Albireo's liver disease drug
Sign up for ANA SmartBrief
Nursing news and information
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.